Oncology Innovations: ENVISION Trial Results, AI Integration, and Real-Time Symptom Monitoring

Recent developments in oncology highlight significant advances in bladder cancer treatment, artificial intelligence integration, and real-time patient monitoring systems. The phase 3 ENVISION trial demonstrated promising results for a novel chemoablative gel therapy, while new technologies aim to personalize cancer care through AI-driven precision medicine and continuous symptom tracking.

The single-arm, open-label ENVISION trial evaluated complete response rates and duration of response by EORTC recurrence score subgroups in patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer. The study examined mitomycin (UGN-102), a novel non-surgical chemoablative gel therapy that can be administered outpatient without discontinuing blood thinners, in 240 patients with the primary end point of 3-month CR rate. In those who received all 6 planned doses, the 3-month CR rate was 80% (95% CI, 73.9%-84.5%), with a response probability of 82% (95% CI, 75.9%-87.1%) at 1 year, a median DOR that was not estimable at a median follow-up of 13.9 months, and a favorable toxicity profile with 57% of patients experiencing a treatment-emergent adverse effect. These data provide powerful evidence supporting the efficacy of chemoablative therapy, with subsequent post hoc analyses presented at the 2026 Genitourinary Cancers Symposium.

In the realm of precision oncology, artificial intelligence is emerging as a foundational pillar that will redefine how we approach healthcare broadly and cancer care specifically. AI accelerates precision oncology, turning genomic data into smarter, targeted cancer treatments, fewer adverse effects, and faster decisions for personalized care. Precision oncology focuses on the granular level of care, including identifying biomarkers by pinpointing specific genetic mutations or proteins unique to a patient's tumor, targeted drug development by engineering therapies designed to interact specifically with those identified targets, and reducing toxicity by attacking only the cancer cells and sparing healthy tissue. By merging the innovative power of AI with the biological accuracy of precision oncology, clinicians can imagine a new era of medicine where AI acts as a catalyst, helping doctors navigate vast genomic landscapes to find the right treatment for the right patient at the right time.

Meanwhile, at Sylvester Comprehensive Cancer Center, the development of OncoPRO represents a next-generation symptom monitoring program designed to detect problems earlier, strengthen patient safety and deliver more responsive, data-driven cancer care. OncoPRO advances this model by embedding patient-reported outcomes captured by the National Cancer Institute-created Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events directly into the health system's electronic medical record. This integration transforms symptom tracking from a parallel process into a core component of clinical care, creating a continuous, real-time feedback loop between patients and their care teams.

Phase 1 and phase 2 trial patients receive structured symptom questionnaires every two weeks through the electronic health record system, with responses flowing directly into the medical record. When predefined safety thresholds are crossed, best practice alerts prompt immediate review and intervention. This immediacy is critical when therapies can escalate from mild symptoms to serious toxicities very quickly, thus allowing clinicians to modify treatments as needed and prevent adverse events or treatment discontinuation. OncoPRO strengthens the safety of clinical trials, enhancing data capture and reporting, and advances a more responsive, patient-centered model of care aligned with the future of oncology.

In other oncology developments, researchers are examining the rising incidence of early-onset colorectal cancer and its defining clinical characteristics. Unlike traditional CRC, where roughly 40% of tumors arise on the right side and 60% on the left, early onset CRC is characterized by an overwhelming predominance of left-sided distal tumors, frequently at the rectosigmoid junction, suggesting it is a biologically distinct disease entity. Microbiome alterations potentially driven by dietary or environmental factors concentrated in the distal colon could serve as a primary oncogenic catalyst.

Additionally, the clinical utility and prognostic significance of the Breast Cancer Index in patients with breast cancer receiving adjuvant endocrine therapy continues to be validated. Although BCI is most commonly linked with decision making for extended adjuvant therapy in the 5-to-10-year post-diagnosis window, the assay is also validated as a prognostic tool for early recurrence in the 0-to-5-year interval, providing comprehensive risk insight across a full 10-year trajectory. By leveraging BCI's dual prognostic capabilities spanning both early and late recurrence windows, endocrine therapy strategies can more effectively be tailored to each patient's individual risk profile.